<span item_type="fundamental" item_id="83c63fb2925d7143883a63e0aa1b3c92" counter_id="ST/US/XAGE" env="prod"></span><span item_type="announcement" item_id="582804946581193473" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 425.86 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.83.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -1.466 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Gross sales for the three months ended September 30, 2025 were $454,106, compared to $58,915 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li><li>Gross sales for the nine months ended September 30, 2025 were $1,525,027, compared to $71,235 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Net loss for the three months ended September 30, 2025 was - $1,429,755, compared to - $2,878,481 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li><li>Net loss for the nine months ended September 30, 2025 was - $4,822,060, compared to - $9,453,978 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li><li>Gross profit for the three months ended September 30, 2025 was $254,463, compared to $15,679 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li><li>Gross profit for the nine months ended September 30, 2025 was $826,944, compared to $27,707 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the nine months ended September 30, 2025 was - $3,022,899, compared to - $3,121,193 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li><li>Net cash used in investing activities for the nine months ended September 30, 2025 was - $164,224, compared to - $748,796 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li><li>Net cash provided by financing activities for the nine months ended September 30, 2025 was $4,139,212, compared to $2,094,853 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The Elevai Acquisition contributed significantly to the increase in sales, with Elevai Skincare’s products generating revenue of approximately $2.5 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to continue the commercialization of its cosmetic products and anticipates cost savings from restructuring activities. The pending THPlasma Merger is expected to close in the first quarter of 2026, which is anticipated to enhance the company’s business operations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li><li><strong>Non-Core Business</strong>: The company is exploring raising additional capital and acquiring cash flow generating assets or businesses to alleviate substantial doubt about its ability to continue as a going concern.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li></ul>

Longevity Health | 10-Q: FY2025 Q3 Revenue: USD 425.86 K